We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
Read MoreHide Full Article
On Oct 16, we issued an updated research report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) . The company’s top line mainly consists of milestone payments and collaboration revenues on the net sales of Idhifa, which is owned by its partner Celgene Corporation . Its wholly owned product Tibsovo was approved by the FDA in July 2018 and holds immense commercial potential in the acute myeloid leukemia (AML) market.
Although Tibsovo did not contribute to Agios’ revenues in the second quarter, it is likely to boost the company’s top line in the future quarters.
Tibsovo, an isocitrate dehydrogenase-1 (IDH1) inhibitor, is indicated for treating relapsed or refractory (R/R AML) with a susceptible IDH1 mutation. The candidate was approved a month before the expected action date. A regulatory filing for the candidate in the EU is expected during the fourth quarter of 2018 for the same indication.
Tibsovo is also being evaluated in a phase I study for treating advanced hematologic malignancies and in a phase I/II combination study with Celgene’s Vidaza for attending newly diagnosed AML patients, who are not eligible for an intensive chemotherapy.
Pipeline Promises Potential
Agios’ lead rare genetic diseases candidate, AG-348, is under evaluation in a phase II program on adult, transfusion-independent patients with Pyruvate kinase (PK) deficiency. In June, the company announced the initiation of the phase III ACTIVATE analysis on the candidate for treating adult patients with PK deficiency, who do not undergo regular blood transfusions.
AG-348 is also being evaluated in a phase III program called ACTIVATE-T, a single-arm pivotal study on adult PK deficiency patients, who receive regular blood transfusions. The company also plans to begin a phase II proof of concept evaluation in the fourth quarter of 2018 on AG-348 for addressing thalassemia.
Agios is conducting phase I programs on AG-881 for treating patients with advanced IDH1 or IDH2 mutant-positive solid tumors including glioma.
The company plans to submit an investigational new drug (IND) application for AG-636, an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase (DHODH) for treating hematologic malignancies during the fourth quarter.
However, Agios’ heavy dependence on partner Celgene for reaping revenues is a persistent concern. Stiff competition is another headwind for the company as several other industry players like AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) , Eli Lilly and Roche have their candidates lined up for treating cancer and rare genetic metabolic disorders by targeting cellular metabolism.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
On Oct 16, we issued an updated research report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) . The company’s top line mainly consists of milestone payments and collaboration revenues on the net sales of Idhifa, which is owned by its partner Celgene Corporation . Its wholly owned product Tibsovo was approved by the FDA in July 2018 and holds immense commercial potential in the acute myeloid leukemia (AML) market.
Although Tibsovo did not contribute to Agios’ revenues in the second quarter, it is likely to boost the company’s top line in the future quarters.
Tibsovo, an isocitrate dehydrogenase-1 (IDH1) inhibitor, is indicated for treating relapsed or refractory (R/R AML) with a susceptible IDH1 mutation. The candidate was approved a month before the expected action date. A regulatory filing for the candidate in the EU is expected during the fourth quarter of 2018 for the same indication.
Tibsovo is also being evaluated in a phase I study for treating advanced hematologic malignancies and in a phase I/II combination study with Celgene’s Vidaza for attending newly diagnosed AML patients, who are not eligible for an intensive chemotherapy.
Pipeline Promises Potential
Agios’ lead rare genetic diseases candidate, AG-348, is under evaluation in a phase II program on adult, transfusion-independent patients with Pyruvate kinase (PK) deficiency. In June, the company announced the initiation of the phase III ACTIVATE analysis on the candidate for treating adult patients with PK deficiency, who do not undergo regular blood transfusions.
AG-348 is also being evaluated in a phase III program called ACTIVATE-T, a single-arm pivotal study on adult PK deficiency patients, who receive regular blood transfusions. The company also plans to begin a phase II proof of concept evaluation in the fourth quarter of 2018 on AG-348 for addressing thalassemia.
Agios is conducting phase I programs on AG-881 for treating patients with advanced IDH1 or IDH2 mutant-positive solid tumors including glioma.
The company plans to submit an investigational new drug (IND) application for AG-636, an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase (DHODH) for treating hematologic malignancies during the fourth quarter.
However, Agios’ heavy dependence on partner Celgene for reaping revenues is a persistent concern. Stiff competition is another headwind for the company as several other industry players like AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) , Eli Lilly and Roche have their candidates lined up for treating cancer and rare genetic metabolic disorders by targeting cellular metabolism.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>